Castle Biosciences received approval from the New York State Department of Health for its AdvanceAD-Tx test, a non-invasive gene expression profile designed to guide systemic therapy for patients aged 12 and older with moderate-to-severe atopic dermatitis. This test helps clinicians select the most effective treatment by analyzing a patient's disease biology from a skin sample, improving personalized care and potentially reducing ineffective treatment cycles. The approval expands access to this precision medicine tool in New York, supporting better outcomes for millions affected by this chronic skin condition. Castle now holds NY approval for all tests in its dermatology and ophthalmology portfolios, enhancing its diagnostic reach.
Borders & Southern Petroleum is progressing discussions with multiple parties to farm out its Darwin oil discovery in the Falkland Islands, amid growing investor interest driven by accelerated development of the Sea Lion oil project. The company owns...
Solana (SOL) has surged more than 24% in the past week and 43% over the last month, reclaiming the $100 price level. Institutional and whale investors, including DeFi Development Corp (DFDV), which added 19,000 SOL to its 2.3 million token holdings, ...
Dunkin' and BARK opened their first official dog drive-thru in Quincy, Massachusetts, on National Dog Day, offering dog treats, limited-edition bandanas, and plush toys inspired by Dunkin's menu. The event supports the Dunkin' Joy in Childhood Founda...
US-listed XRP ETFs attracted $28.14 million on August 26, marking the second-largest daily inflow in 2026, led by Bitwise with $13.12 million. Whale wallets accumulated about 460 million XRP tokens, the strongest since February, signaling strong inst...
At Bitcoin Asia 2026 in Hong Kong, former Binance CEO Changpeng Zhao predicted Bitcoin will overtake gold's significance during the next bull market cycle. While gold's market cap is about $32.4 trillion, Bitcoin currently holds $1.6 trillion, with Z...
